Program

PO1-9-15

SPIREL® SUPPLEMENTATION EFFECTS IN AIDS PATIENTS WITH DELAYED DIAGNOSIS OF HIV: AN OPEN RANDOMIZED CONTROLLED TRIAL

[Speaker] Lizette Gil:1
[Co-author] Rosario Gravier:1, Angelica Reyes:1, Angely Cardenas:1, Milena Duque:1
1:Institute of Pharmacy and Food Havana University, Institute of Tropical Medicine Pedro Kouri, Cuba

Acquired immune deficiency syndrome (aids) constitutes a global health problem. During antiretroviral therapy (ART) oxidative stress status points out the need for antioxidants in these patients indeed pre or post exposition to ART. In an open randomized control trial, 40 aids delayed diagnosis patients whose received prescription of ART were selected to be covered under Hospital-IPK monitoring consults. Patients received Spirel® tablets (200 mg) three times a day or only ART during 6 months. The baseline assessment and the final follow-up of the patients who meet the inclusion criteria includes doing some lab tests to determine the absolute count of CD4 + T lymphocyte, viral load, chemical, hematological and seven plasma redox indexes. Final variables values were compared with the baseline value and between groups. The incidence of opportunistic infection and adverse reactions were identified during the follow-up. Also quality of life questionnaires were assessed at pre and post study period in both groups. There were significant differences regarding positive change in five redox indexes in Spirel® group compared to those of ART group (p˂0,05). No significant difference was found in the hematological and biochemical indexes at the end of the study for Spirel® group respect ART group. Quality of life improvement was demonstrated related the use of Spirel® concomitant to ART. Patient survival was 50 percent higher in Spirel® group respect ART group. Spirel® antioxidant beneficial effect was demonstrated, without any toxic influence during the twelve months-study conducted in HIV/aids Cuban patients with delayed diagnosis.
Advanced Search